133.02
前日終値:
$133.74
開ける:
$134.085
24時間の取引高:
4.82M
Relative Volume:
0.78
時価総額:
$231.52B
収益:
$43.11B
当期純損益:
$13.94B
株価収益率:
16.64
EPS:
7.9963
ネットキャッシュフロー:
$6.78B
1週間 パフォーマンス:
-0.69%
1か月 パフォーマンス:
+0.06%
6か月 パフォーマンス:
+6.54%
1年 パフォーマンス:
+17.34%
Abbott Laboratories Stock (ABT) Company Profile
名前
Abbott Laboratories
セクター
電話
(224) 667-6100
住所
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
ABT を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
ABT
Abbott Laboratories
|
133.02 | 232.77B | 43.11B | 13.94B | 6.78B | 7.9963 |
![]()
BSX
Boston Scientific Corp
|
95.90 | 143.29B | 18.49B | 2.50B | 3.49B | 1.6801 |
![]()
SYK
Stryker Corp
|
369.24 | 140.03B | 23.82B | 2.92B | 4.02B | 7.5574 |
![]()
MDT
Medtronic Plc
|
98.33 | 126.25B | 34.20B | 4.69B | 5.30B | 3.6218 |
![]()
EW
Edwards Lifesciences Corp
|
76.72 | 44.95B | 5.69B | 1.41B | 577.90M | 6.9828 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2025-07-18 | アップグレード | Jefferies | Hold → Buy |
2025-06-16 | 開始されました | Leerink Partners | Market Perform |
2024-10-08 | 開始されました | Oppenheimer | Outperform |
2024-09-19 | 開始されました | Piper Sandler | Overweight |
2024-07-30 | ダウングレード | Edward Jones | Buy → Hold |
2024-05-30 | 開始されました | Goldman | Buy |
2023-07-21 | アップグレード | Wolfe Research | Underperform → Peer Perform |
2023-05-30 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
2023-04-20 | 繰り返されました | Barclays | Overweight |
2023-04-20 | 繰り返されました | Bernstein | Outperform |
2023-04-20 | 繰り返されました | JP Morgan | Overweight |
2023-04-20 | 繰り返されました | Raymond James | Outperform |
2023-04-20 | 繰り返されました | UBS | Buy |
2023-04-20 | 繰り返されました | Wolfe Research | Underperform |
2023-03-29 | 開始されました | UBS | Buy |
2022-10-26 | 開始されました | Mizuho | Neutral |
2022-10-18 | 開始されました | Barclays | Overweight |
2022-10-12 | 開始されました | Jefferies | Hold |
2022-07-06 | 開始されました | Wolfe Research | Underperform |
2022-03-02 | 再開されました | BofA Securities | Buy |
2022-01-27 | 繰り返されました | Credit Suisse | Outperform |
2022-01-27 | 繰り返されました | Morgan Stanley | Overweight |
2022-01-27 | 繰り返されました | Raymond James | Outperform |
2022-01-27 | 繰り返されました | UBS | Buy |
2021-12-10 | 開始されました | RBC Capital Mkts | Outperform |
2021-10-27 | アップグレード | Atlantic Equities | Neutral → Overweight |
2021-10-14 | 開始されました | Redburn | Neutral |
2021-05-25 | 開始されました | Barclays | Overweight |
2021-04-15 | 開始されました | Atlantic Equities | Neutral |
2021-01-28 | アップグレード | BTIG Research | Neutral → Buy |
2020-09-11 | 開始されました | Wolfe Research | Outperform |
2020-06-01 | ダウングレード | Goldman | Neutral → Sell |
2020-03-05 | 開始されました | Citigroup | Buy |
2020-02-13 | 開始されました | Goldman | Neutral |
2020-02-06 | 再開されました | BTIG Research | Neutral |
2020-01-02 | ダウングレード | Guggenheim | Buy → Neutral |
2019-06-13 | 繰り返されました | BofA/Merrill | Buy |
2019-02-07 | 繰り返されました | BofA/Merrill | Buy |
2019-01-02 | ダウングレード | Citigroup | Neutral → Sell |
2018-11-30 | アップグレード | Goldman | Neutral → Buy |
2018-10-16 | 開始されました | Barclays | Overweight |
2018-06-27 | 開始されました | Bernstein | Outperform |
2018-01-30 | 繰り返されました | Citigroup | Neutral |
2018-01-25 | 繰り返されました | Stifel | Buy |
2018-01-25 | アップグレード | William Blair | Mkt Perform → Outperform |
2018-01-03 | 開始されました | Evercore ISI | Outperform |
2018-01-02 | アップグレード | JP Morgan | Neutral → Overweight |
2018-01-02 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
2017-10-19 | 繰り返されました | RBC Capital Mkts | Outperform |
2017-10-19 | 繰り返されました | Stifel | Buy |
すべてを表示
Abbott Laboratories (ABT) 最新ニュース
Evercore ISI Adjusts Abbott Laboratories Price Target to $144 From $140, Maintains Outperform Rating - MarketScreener
Abbott Laboratories' (NYSE:ABT) Returns On Capital Are Heading Higher - Yahoo
The Zacks Analyst Blog Highlights Advanced Micro Devices, Abbott Laboratories and Micron Technology - Zacks Investment Research
Thyroid Cancer Diagnostics Market Size to Surge USD 5.22 Billion at 5.34% CAGR by 2034 - GlobeNewswire Inc.
Precision Trading with Abbott Laboratories (ABT) Risk Zones - news.stocktradersdaily.com
Is Abbott Laboratories (ABL) stock positioned for secular growthPortfolio Update Summary & Low Drawdown Trading Strategies - newser.com
What candlestick patterns are forming on Abbott LaboratoriesMarket Risk Analysis & Risk Controlled Swing Alerts - newser.com
Top Stock Reports for AMD, Abbott & Micron Technology - The Globe and Mail
Abbott (ABT) Laps the Stock Market: Here's Why - Yahoo Finance
How Abbott Laboratories (ABT) Affects Rotational Strategy Timing - news.stocktradersdaily.com
Abbott Laboratories (ABT): Exploring Valuation as Steady Gains Draw Investor Interest in 2024 - simplywall.st
Abbott (ABT) Is Considered a Good Investment by Brokers: Is That True? - Yahoo
‘Few missions more meaningful than improving global health,’ says HR expert - Silicon Republic
Why analysts recommend Abbott Laboratories (ABL) stockJuly 2025 Breakouts & Long-Term Safe Investment Ideas - newser.com
Ready To Pass On Abbott Laboratories (NYSE:ABT)? Think Again - 富途牛牛
Goldman Sachs Maintains Abbott Laboratories(ABT.US) With Buy Rating - 富途牛牛
Abbott Laboratories (ABT) Maintains Strong MedTech Growth Outlook - Insider Monkey
2 Profitable Stocks to Consider Right Now and 1 We Find Risky - FinancialContent
Abbott Laboratories Q3 Earnings Preview: Profit boost expected - MSN
Abbott Gains Diabetes Tech Expansion Opportunity Following Earnings Beat and Insider Sale - MSN
Europe Clinical Nutrition Market to hit US$ 36.63 Billion by 2033 - openPR.com
Will Abbott Laboratories (Common Stock) (ABL0) stock attract long term capital inflowsJuly 2025 PreEarnings & Low Risk High Reward Ideas - newser.com
Goldman Sachs Adjusts Price Target on Abbott Laboratories to $157 From $153, Maintains Buy Rating - MarketScreener
Abbott (ABT) Gains Attention with Inclusion in Goldman Sachs Con - GuruFocus
Will Abbott Laboratories (ABL) stock return to pre crash levelsJuly 2025 Highlights & Consistent Growth Stock Picks - newser.com
Abbott wins Health Canada approval for Esprit drug-eluting, dissolving scaffold - MassDevice
Union Bancaire Privee UBP SA Sells 30,201 Shares of Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories $ABT is Paradiem LLC's 5th Largest Position - MarketBeat
Synlait to sell North Island assets to Abbott for $178m - FoodBev Media
Health Canada authorises Abbott’s Esprit BTK system for CLTI treatment - Medical Device Network
HB Wealth Management LLC Cuts Position in Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories $ABT Shares Bought by Janney Montgomery Scott LLC - MarketBeat
How buyback programs support Abbott Laboratories stockMarket Risk Summary & Long-Term Capital Growth Ideas - newser.com
How Abbott Laboratories stock responds to policy changesJuly 2025 Market Mood & High Yield Stock Recommendations - newser.com
Synlait Milk agrees North Island asset sale to Abbott Laboratories - Global Food Industry News
Strategies to average down on Abbott LaboratoriesRecession Risk & AI Based Buy and Sell Signals - newser.com
Abbott Laboratories (ABT): A Healthcare Leader Offering Dividend Value and Growth - MSN
Can swing trading help recover from Abbott Laboratories lossesMarket Weekly Review & Target Return Focused Picks - newser.com
Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It - sharewise.com
Detecting support and resistance levels for Abbott LaboratoriesMarket Activity Recap & Weekly Sector Rotation Insights - newser.com
NZ's Synlait cuts annual loss, inks asset sale deal; shares surge - Reuters
Smith Chas P & Associates PA Cpas Sells 2,167 Shares of Abbott Laboratories $ABT - MarketBeat
GC Wealth Management RIA LLC Grows Position in Abbott Laboratories $ABT - MarketBeat
Klein Pavlis & Peasley Financial Inc. Acquires Shares of 17,000 Abbott Laboratories $ABT - MarketBeat
What to Expect From Abbott Laboratories' Next Quarterly Earnings Report - Yahoo Finance
Moody Lynn & Lieberson LLC Sells 12,285 Shares of Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories $ABT Shares Sold by Fort Washington Investment Advisors Inc. OH - MarketBeat
Can volume confirm reversal in Abbott Laboratories2025 Fundamental Recap & Real-Time Market Sentiment Alerts - newser.com
China’s Bright Dairy to Sell New Zealand Assets to Abbott for USD170 Million - 一财全球Yicai Global
Synlait Milk reports full-year loss ahead of asset sale - RNZ
Synlait sells Pōkeno site for $307m, manufacturing woes batter bottom line - ThePost.co.nz
Abbott Laboratories (ABT) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):